Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01768273 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam
A Phase 1 study, sponsored by Global Alliance for TB Drug Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01768273 is a Phase 1 study that has completed, run by Global Alliance for TB Drug Development. The registered enrollment target is 14 participants.
The verdict
NCT01768273, a Phase 1 study, has completed, sponsored by Global Alliance for TB Drug Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of PA-824 when given with a single dose of midazolam, and to determine whether PA-824 inhibits CYP3A to a clinically important degree as measured by the effect of PA-824 on the pharmacokinetics of midazolam, a known CYP3A substrate.
Interventions
- DRUG Midazolam
- DRUG PA-824
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01768273
The ClinicalTrials.gov registry entry for NCT01768273 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Global Alliance for TB Drug Development, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.
NCT01768273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01768273 about?
NCT01768273 is a clinical study titled "Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam". The purpose of this study is to determine the safety and tolerability of PA-824 when given with a single dose of midazolam, and to determine whether PA-824 inhibits CYP3A to a clinically important degree as measured by the effect of PA-824 on the pharmacokinetics of midazolam, a known CYP3A substrat...
What is the current status of trial NCT01768273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2009-12. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01768273?
The interventions under investigation include: Midazolam (DRUG), PA-824 (DRUG).
Who is sponsoring clinical trial NCT01768273?
This trial is sponsored by Global Alliance for TB Drug Development, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.